{"filing":{"accession_number":"0001104659-26-082250","cik":"0001130598","ticker":"TRAW","company_name":"Traws Pharma, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"tm2620113d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926082250/tm2620113d1_8k.htm"},"events":[{"id":16813,"run_id":15040,"accession_number":"0001104659-26-082250","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Traws Pharma held its Annual Meeting of Stockholders on July 8, 2026, with stockholders voting on five proposals: election of seven directors, amendment to the 2021 Incentive Compensation Plan to increase available shares by 2,000,000, ratification of KPMG LLP as independent auditor, approval of warrant issuance under Nasdaq Rule 5635(d), and adjournment authority. All five proposals passed with detailed vote tallies disclosed.","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15014,"accession_number":"0001104659-26-082250","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Incentive Compensation Plan that increases the share pool available for issuance by 2,000,000 shares and makes administrative changes. This is a compensatory arrangement amendment affecting equity grants and incentive awards, which falls squarely within exec_compensation. The event is material because it expands the equity pool available for executive and employee compensation and was subject to stockholder vote.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:34:06.844092+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15015,"accession_number":"0001104659-26-082250","item_number":"5.07","item_title":"Submission of Matters to a Vote","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Traws Pharma's Annual Meeting of Stockholders held on July 8, 2026. The filing presents voting outcomes for five proposals: election of seven directors, amendment to the 2021 Incentive Compensation Plan to increase available shares by 2,000,000, ratification of KPMG LLP as independent auditor, approval of warrant issuance under Nasdaq Rule 5635(d), and adjournment authority. All proposals passed. The disclosure includes detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal, which is the hallmark of shareholder_vote_results classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:34:06.844092+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15014,"accession_number":"0001104659-26-082250","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Incentive Compensation Plan that increases the share pool available for issuance by 2,000,000 shares and makes administrative changes. This is a compensatory arrangement amendment affecting equity grants and incentive awards, which falls squarely within exec_compensation. The event is material because it expands the equity pool available for executive and employee compensation and was subject to stockholder vote.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:34:06.844092+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-07-09"},{"id":15015,"accession_number":"0001104659-26-082250","item_number":"5.07","item_title":"Submission of Matters to a Vote","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Traws Pharma's Annual Meeting of Stockholders held on July 8, 2026. The filing presents voting outcomes for five proposals: election of seven directors, amendment to the 2021 Incentive Compensation Plan to increase available shares by 2,000,000, ratification of KPMG LLP as independent auditor, approval of warrant issuance under Nasdaq Rule 5635(d), and adjournment authority. All proposals passed. The disclosure includes detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal, which is the hallmark of shareholder_vote_results classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:34:06.844092+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-07-09"}]}